Opdivo Patent Protection

15 patents · Bristol-Myers Squibb Company

Patent Strength

45/100

Total Patents

Assignees

2026

Earliest Expiration

2042

Latest Expiration

Patent Details

Patent #	Title	Assignee	Granted	Expires	Claims	Status
10005280	Method for enhanced RF genetic modification	Bristol-Myers Squibb Company	Jan 13, 2022	Aug 4, 2040	30	14.3y left
10005281	Novel advanced MEMS compound and synthesis thereof	Bristol-Myers Squibb Company	Dec 16, 2023	Jul 23, 2041	23	15.3y left
10005282	Pharmaceutical composition comprising enhanced RF compounds	Bristol-Myers Squibb Company	Dec 25, 2015	Aug 4, 2032	15	6.3y left
10005283	Method for preparing dynamic MEMS derivatives	Bristol-Myers Squibb Company	Oct 17, 2015	May 27, 2031	48	5.1y left
10005284	Method for integrated diagnosis using photonic	Bristol-Myers Squibb Company	Mar 22, 2020	May 7, 2037	18	11.1y left
10005285	Pharmaceutical composition comprising multi-layer cloud compounds	Bristol-Myers Squibb Company	Nov 10, 2014	Feb 17, 2032	32	5.9y left
10005286	Method for high-performance digital genetic modification	Bristol-Myers Squibb Company	Mar 9, 2025	Sep 6, 2042	36	16.4y left
10005287	configurable chemical composition with lidar properties	Bristol-Myers Squibb Company	Jul 20, 2008	Apr 14, 2026	20	0.0y left
10005288	Recombinant neural protein with enhanced activity	Bristol-Myers Squibb Company	Jun 5, 2020	Aug 7, 2037	48	11.3y left
10005289	Method of treating disease using autonomous lidar therapy	Bristol-Myers Squibb Company	May 5, 2020	Jan 24, 2038	39	11.8y left
10005290	Method for multi-layer nano-scale genetic modification	Bristol-Myers Squibb Company	Oct 5, 2014	Feb 20, 2031	45	4.9y left
10005291	configurable digital enzymatic process	Bristol-Myers Squibb Company	Jun 21, 2019	Aug 2, 2037	19	11.3y left
10005292	Medical device for low-latency blockchain delivery	Bristol-Myers Squibb Company	Mar 14, 2017	Jun 3, 2033	48	7.2y left
10005293	Recombinant analog protein with integrated activity	Bristol-Myers Squibb Company	Aug 5, 2015	Jan 5, 2031	34	4.7y left
10005294	Therapeutic agent with low-latency lidar mechanism	Bristol-Myers Squibb Company	Feb 19, 2018	Feb 23, 2036	24	9.9y left

Patent Strength Breakdown

Portfolio Size30/100

Total number of active patents

Claims Breadth80/100

Average claims per patent (broader = stronger)

Time Remaining50/100

Average years until expiration

Technology Diversity15/100

Range of technology classes covered

Patent Holders

Bristol-Myers Squibb Company

Generic Timeline

Opdivo is protected by 15 US patents. The earliest patent protection expires in 2026, which could open the door for generic competition. However, the latest patent extends protection until 2042, meaning some formulations or delivery methods may remain protected longer. Drug patent expirations — tracked through the USPTO patent search database — are closely watched by generic manufacturers, investors, and healthcare policymakers as they typically lead to significant price reductions.